Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs

Abstract Background Canine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was ev...

Full description

Bibliographic Details
Main Authors: Thomas Geurden, Robert Six, Csilla Becskei, Steven Maeder, Anne Lloyd, Sean Mahabir, Josephus Fourie, Julian Liebenberg
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Parasites & Vectors
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13071-017-2358-3
id doaj-d246e0749d794d2b8876acd64a252f63
record_format Article
spelling doaj-d246e0749d794d2b8876acd64a252f632020-11-25T00:38:28ZengBMCParasites & Vectors1756-33052017-09-011011610.1186/s13071-017-2358-3Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogsThomas Geurden0Robert Six1Csilla Becskei2Steven Maeder3Anne Lloyd4Sean Mahabir5Josephus Fourie6Julian Liebenberg7ZoetisZoetisZoetisZoetisZoetisZoetisClinvet InternationalClinvet InternationalAbstract Background Canine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was evaluated in twenty-four dogs randomly allocated to either a placebo-treated group or one of two sarolaner-treated groups. At 21 or 28 days after treatment administration, dogs were infested with 50 ± 4 Dermacentor reticulatus ticks of which 25% were confirmed to be infected with Babesia canis. Blood samples were collected from each dog prior to tick infestation and weekly thereafter until 49 days after infestation. The blood was assayed for B. canis antibodies using an indirect immunofluorescence test (IFAT) and for B. canis DNA by PCR assay. A dog was a priori defined as B. canis-positive if it tested positive by both IFAT and PCR at any time during the study. Results No treatment-related adverse reactions were recorded during the study. All placebo-treated animals displayed clinical signs due to babesiosis and tested positive on both IFAT and PCR. None of the sarolaner-treated animals displayed any clinical symptoms or tested positive on both IFAT and PCR, resulting in a 100% efficacy in the prevention of canine babesiosis (P = 0.0002). Conclusion When given 21 or 28 days before tick infestation, a single treatment with sarolaner at the minimum recommended label dose of 2.0 mg per kg body weight prevented the transmission of B. canis by D. reticulatus to dogs.http://link.springer.com/article/10.1186/s13071-017-2358-3DogsDermacentor reticulatusBabesia canisBabesiosisTransmissionEfficacy
collection DOAJ
language English
format Article
sources DOAJ
author Thomas Geurden
Robert Six
Csilla Becskei
Steven Maeder
Anne Lloyd
Sean Mahabir
Josephus Fourie
Julian Liebenberg
spellingShingle Thomas Geurden
Robert Six
Csilla Becskei
Steven Maeder
Anne Lloyd
Sean Mahabir
Josephus Fourie
Julian Liebenberg
Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
Parasites & Vectors
Dogs
Dermacentor reticulatus
Babesia canis
Babesiosis
Transmission
Efficacy
author_facet Thomas Geurden
Robert Six
Csilla Becskei
Steven Maeder
Anne Lloyd
Sean Mahabir
Josephus Fourie
Julian Liebenberg
author_sort Thomas Geurden
title Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
title_short Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
title_full Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
title_fullStr Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
title_full_unstemmed Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
title_sort evaluation of the efficacy of sarolaner (simparica®) in the prevention of babesiosis in dogs
publisher BMC
series Parasites & Vectors
issn 1756-3305
publishDate 2017-09-01
description Abstract Background Canine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was evaluated in twenty-four dogs randomly allocated to either a placebo-treated group or one of two sarolaner-treated groups. At 21 or 28 days after treatment administration, dogs were infested with 50 ± 4 Dermacentor reticulatus ticks of which 25% were confirmed to be infected with Babesia canis. Blood samples were collected from each dog prior to tick infestation and weekly thereafter until 49 days after infestation. The blood was assayed for B. canis antibodies using an indirect immunofluorescence test (IFAT) and for B. canis DNA by PCR assay. A dog was a priori defined as B. canis-positive if it tested positive by both IFAT and PCR at any time during the study. Results No treatment-related adverse reactions were recorded during the study. All placebo-treated animals displayed clinical signs due to babesiosis and tested positive on both IFAT and PCR. None of the sarolaner-treated animals displayed any clinical symptoms or tested positive on both IFAT and PCR, resulting in a 100% efficacy in the prevention of canine babesiosis (P = 0.0002). Conclusion When given 21 or 28 days before tick infestation, a single treatment with sarolaner at the minimum recommended label dose of 2.0 mg per kg body weight prevented the transmission of B. canis by D. reticulatus to dogs.
topic Dogs
Dermacentor reticulatus
Babesia canis
Babesiosis
Transmission
Efficacy
url http://link.springer.com/article/10.1186/s13071-017-2358-3
work_keys_str_mv AT thomasgeurden evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT robertsix evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT csillabecskei evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT stevenmaeder evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT annelloyd evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT seanmahabir evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT josephusfourie evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
AT julianliebenberg evaluationoftheefficacyofsarolanersimparicainthepreventionofbabesiosisindogs
_version_ 1725297336918212608